A Phase I Study of BR790 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2021-05-18
- Last Posted Date
- 2021-05-18
- Lead Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT04891653
A Real World Study on the Efficacy and Safety of Lacosamide as Add-on Therapy for Focal-onset Epilepsy
- Conditions
- EpilepsyFocal-Onset Seizure
- Interventions
- First Posted Date
- 2021-02-04
- Last Posted Date
- 2021-02-04
- Lead Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT04737837
- Locations
- 🇨🇳
The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
🇨🇳The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
🇨🇳Shenzhen Children's Hospital, Shenzhen, Guangdong, China
A Clinical Study on the Safety and Efficacy of GP681 Tablets in the Treatment of Uncomplicated Acute Influenza
Phase 2
Completed
- Conditions
- Influenza
- Interventions
- Drug: GP681 tabletDrug: GP681 Simulant
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Target Recruit Count
- 216
- Registration Number
- NCT04736758
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
Evaluation the Safety and Tolerance of GP681 Tablets in Healthy Subjects
Phase 1
Completed
- Conditions
- Influenza
- Interventions
- Drug: GP681 Tablet
- First Posted Date
- 2021-01-28
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT04729764
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, Shanghai, China
A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients
Phase 2
- Conditions
- BRCA 1 Gene MutationBreast Cancer MetastaticBRCA 2 Gene Mutation
- Interventions
- First Posted Date
- 2020-09-21
- Last Posted Date
- 2020-09-21
- Lead Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Target Recruit Count
- 78
- Registration Number
- NCT04556292
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer
- First Posted Date
- 2020-09-21
- Last Posted Date
- 2021-05-12
- Lead Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Target Recruit Count
- 104
- Registration Number
- NCT04556539
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fujian, China
SC10914 Monotherapy for the mCRPC With g/s BRCA Mutation
Phase 1
- Conditions
- Metastatic Castration Resistant Prostate Cancer
- Interventions
- Drug: S410914 tablet
- First Posted Date
- 2020-07-27
- Last Posted Date
- 2020-07-27
- Lead Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT04486937
Xiyanping Injection Combined With Azithromycin VS Azithromycin for Children With pneumoniaProtozoal Pneumonia
Not Applicable
- Conditions
- Mycoplasma Pneumoniae Pneumonia
- Interventions
- First Posted Date
- 2020-03-05
- Last Posted Date
- 2020-05-19
- Lead Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Target Recruit Count
- 450
- Registration Number
- NCT04296383
Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)
Not Applicable
- Conditions
- COVID-19
- Interventions
- Drug: Lopinavir/ritonavir treatment
- First Posted Date
- 2020-03-04
- Last Posted Date
- 2020-03-04
- Lead Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT04295551
Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia
- Conditions
- 2019 Novel Coronavirus Pneumonia
- Interventions
- First Posted Date
- 2020-02-19
- Last Posted Date
- 2020-05-20
- Lead Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Target Recruit Count
- 426
- Registration Number
- NCT04275388
© Copyright 2025. All Rights Reserved by MedPath